TMCnet News
"Stocks that Standout" picks for today are: BMRN, CYTR, MIPS, TLAN(M2 PressWIRE Via Acquire Media NewsEdge) Jul 13, 2009 StandoutStocks.com "Stocks that Standout" picks for today are: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), CytRx Corporation (NASDAQ: CYTR), MIPS Technologies, Inc. (NASDAQ: MIPS), Talent Alliance, Inc. (PINKSHEETS: TLAN) << << << Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 << << << Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com << << << Jul 13, 2009 -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that patient enrollment has been completed for the Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. The company expects to report initial results in the first half of 2010. "The efficient enrollment of twenty patients is a critical milestone for the MPS IVA program and demonstrates both our commitment to this program and the support and enthusiasm of the MPS IVA patient community. Data generated from this study will be valuable in demonstrating safety and could be instrumental in designing a successful Phase III trial. Assessments from the Phase I/II study such as plasma and urine keratan sulfate levels, pulmonary function and walk tests will be helpful in determining optimal Phase III endpoints," said Henry Fuchs, M.D., Chief Medical Officer of BioMarin. "We appreciate the collaboration of the Morquio community in this important effort, and we hope to develop this new treatment as expeditiously as possible." Christian Hendriksz, MBChB, MSc, FRCPCH, MRCP, Consultant in Metabolic Disorders, Birmingham Children's Hospital, UK, added, "Morquio is a serious and debilitating disease in which accumulation of keratan sulfate results in impaired breathing and walking, recurrent infections, impaired bone and joint function, dysmorphology and an overall impaired quality of life. The rapid accrual of patients for the Phase I/II study speaks to the magnitude of the unmet need for this disease." The Phase I/II study is designed as an open-label, within-patient dose escalation trial in 20 patients followed by a treatment continuation period. During the dose escalation phase of the study, subjects will receive weekly intravenous infusions of BMN-110 in three consecutive 12-week dosing intervals. The objectives of the Phase I/II study will be to evaluate safety, pharmacokinetics, pharmacodynamics and to identify the optimal dose of GALNS for future studies. BioMarin plans to provide an extension study in which all patients in the Phase I/II study will be eligible to participate. BioMarin has developed and manufactures two FDA-approved enzyme replacement therapies, one for the treatment of MPS I and one for the treatment of MPS VI. Naglazyme(R) (galsulfase) for MPS VI is wholly developed and commercialized by BioMarin. Aldurazyme(R) (laronidase) for MPS I is manufactured by BioMarin and marketed by Genzyme Corporation. About MPS IVA Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disorder characterized by deficient activity of N-acetylgalactosamine 6-sulfatase (GALNS)causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax as well as macrophage dysfunction in the lung likely impairs respiratory function and contributes to sinopulmonary infections. Odontoid dysplasia and ligamentous laxity can commonly cause cervical spinal instability and potentially spinal cord compression. Other symptoms may include recurrent infections, hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life. Depending on severity of the disorder, age of diagnosis will vary. Many patients become wheelchair dependent in their second decade of life and undergo numerous surgeries to alleviate life-threatening conditions caused by the underlying enzyme deficiency. The incidence estimates for MPS IVA vary widely, between one in 200,000 live births to one in 300,000 live births. Approximately 400 patients worldwide have been identified and tracked through the International Morquio Organization (IMO) survey. There are already more MPS IVA patients identified through this registry than there are MPS VI patients being treated with Naglazyme worldwide. Based on the number of identified patients to date, the prevalence of patients with MPS IVA appears similar to that with MPS I. About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product that was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU. << << << Jul 13, 2009 -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that its investigational cancer drug INNO-206 caused a dramatic destruction of implanted tumors in an experimental animal model of breast cancer, performing considerably better than the broadly used and generally effective chemotherapeutic drug doxorubicin. In addition to improved efficacy in this animal trial, INNO-206 was comparable in toxicity with doxorubicin based on animal body-weight loss. CytRx has exclusive worldwide rights to INNO-206, a proprietary derivative of doxorubicin. The pro-drug INNO-206 is designed to allow controlled release of doxorubicin and to specifically target the delivery of drug to tumors throughout the body, which could prove more effective and less toxic in cancer patients than doxorubicin. INNO-206 has previously demonstrated safety and tolerability, and optimal dosing has been evaluated, in a Phase I clinical trial. In the animal trial - conducted under the direction of INNO-206 inventor Felix Kratz, Ph.D., Department of Medical Oncology, Clinical Research, at the Tumor Biology Center in Freiburg, Germany - human breast tumor cells were implanted in mice with compromised immune systems to avoid tumor rejection. Seven to eight animals were randomly assigned into each of three experimental groups receiving intravenous injections with either a maximum tolerated dose of INNO-206, a maximum tolerated dose of doxorubicin, or a control solution lacking either compound. At the end of the experiment 43 days after implantation, tumors had increased in volume by an average of approximately 2.7-fold in the control group while tumor growth was marginally inhibited in the doxorubicin group; increasing in volume by approximately 1.9-fold in a result that did not reach statistical significance. By contrast, tumors in the group treated with INNO-206 shrank to approximately one-half their initial volume. The decrease in final tumor volume in INNO-206-treated animals was statistically significant (p<0.05) compared to that of either the control or doxorubicin-treated groups. "We take pride in identifying and developing drugs that hold the promise of treating debilitating diseases that represent unmet medical needs, as well as have therapeutic and commercial potential in multiple disease indications," said Steven A. Kriegsman, CytRx President and CEO. "INNO-206 is one of several drug candidates in CytRx's asset portfolio that meets these criteria due to its apparent ability to target multiple tumor types, making it potentially efficacious in other cancers." "We acquired INNO-206 because of our belief that its pro-drug design could improve the efficacy of doxorubicin, a classic chemotherapeutic agent that has proven effective and is commonly used in treating multiple types of cancer," said Joseph Rubinfeld, Ph.D., co-founder of Amgen, a world-renowned expert in cancer drug development and CytRx Chief Scientific Advisor. "If INNO-206 is better than doxorubicin in treating human breast cancer as it demonstrated in this animal breast cancer trial, then we believe that INNO-206 could be a multi-billion dollar drug." About Breast Cancer Breast cancer is the most common cancer among women in the U.S., with more than 192,000 new cases of invasive breast cancer expected to be diagnosed this year, according to American Cancer Society estimates. More than 40,000 deaths are expected to be attributed to breast cancer in the U.S. in 2009, making it the second leading cause of cancer death in U.S. women. The chance of a woman having invasive breast cancer some time during her life is about one in eight. About INNO-206 INNO-206 is a prodrug of the commonly prescribed chemotherapeutic doxorubicin and was designed to reduce adverse events by controlling release and preferentially targeting the tumor. In a Phase 1 study, doses were administered at up to six times the standard dosing of doxorubicin without an increase in observed side effects over those historically seen with doxorubicin. The Company is evaluating options for a possible Phase 2 clinical trial. About CytRx Corporation CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). << << << Jul 13, 2009 -- MIPS Technologies, Inc. (NASDAQ: MIPS), a leading provider of industry-standard processor architectures and cores for home entertainment, communications, networking and portable multimedia markets, today announced that long-time President and CEO John Bourgoin intends to retire at the end of the calendar year. The Company's board of directors plans to begin an immediate search for a successor, which is expected to take three to six months. Bourgoin will remain president and CEO through the end of the calendar year unless his successor is appointed earlier. "The board accepts John's decision to retire with appreciation for his leadership and with pride in his impact on both MIPS and our industry," said Tony Holbrook, the company's board chairman. "Under John's leadership, MIPS Technologies has emerged as a leading supplier of microprocessor IP, and has garnered a leading share in many consumer electronics market segments. MIPS' processor product portfolio has grown rapidly, helping to propel growth of consumer electronics markets over the past decade. Tremendous opportunities await MIPS Technologies as technology continues to advance across a broad front. We look forward to a seamless transition to John's successor, to lead the company in the next phase of its growth." Bourgoin has been CEO of MIPS Technologies, Inc., since February 1998, and president since 1996. He led MIPS Technologies through its IPO in 1998, through its transition into a pure play IP provider, to become a global leader in the semiconductor IP industry. Today, MIPS Technologies has well over a hundred licensees who have together shipped almost two billion MIPS-Based(tm) products. "I'm honored to have had the opportunity to lead MIPS Technologies for more than a decade. It has been an incredible journey, and I am proud of the company we have built, with a stellar team of employees and leading-edge technology," said Bourgoin. "Now that we have completed the divestiture of our Analog Business Group and bolstered our balance sheet to a strong position despite the challenging economy, it is a good time for me to step down. I am giving ample notice so the board can complete a thorough search, and we can have a smooth transition." About MIPS Technologies, Inc. MIPS Technologies, Inc. (Nasdaq:MIPS) is a leading provider of industry-standard processor architectures and cores that power some of the world's most popular products for the home entertainment, communications, networking and portable multimedia markets. These include broadband devices from Linksys, DTVs and digital consumer devices from Sony, DVD recordable devices from Pioneer, digital set-top boxes from Motorola, network routers from Cisco, 32-bit microcontrollers from Microchip Technology and laser printers from Hewlett-Packard. Founded in 1998, MIPS Technologies is headquartered in Sunnyvale, California, with offices worldwide. << << << Jul 10, 2009 -- Talent Alliance, Inc. (PINKSHEETS: TLAN) announced today that it has executed a Letter of Intent to jointly market its TalentExchange platform in China with one of China's leading recruitment firms, Global Talent. Through the partnership, the companies will bring together two cutting edge technologies into a single offering designed to improve efficiencies in the talent acquisition process, and jointly market and promote them in China. "The partnership with Global Talent is a tremendous win for our business in China," said Brian Davis, CEO of Talent Alliance. "We have done much more that select a marketing partner; we entered into strategic relationship with one of the most progressive and forward thinking recruitment groups in China. We will bring together Global Talent's CloudATS and our TalentExchange products to offer a solution to employers and recruiters not currently available anywhere on the market. Global Talent brings with it a portfolio of large clients in China and we add this exclusive technology to the mix for a great potential channel for rapid expansion in China." The ChinaTalentExchange(r) and Global Talent's CloudATS are both currently live and operating independently but will be brought together by a joint development process. The TalentExchange marketplace supports and greatly streamlines the hiring process for companies and improves the marketing and submission process for recruiters. ChinaTalentExchange is free to register and any fees associated with the successful hire of a candidate only occur on a contingency basis with a full money back guarantee to the employers. About Talent Alliance Based in Austin, Texas and Shanghai, China -- Talent Alliance, Inc. provides talent management and talent acquisition technology applications and resources in the United States and The People's Republic of China. Talent Alliance provides world class permanent placement recruiting, contingent staffing, employee leasing and benefits management services, and proprietary talent acquisition technology solutions to small, medium sized businesses and multi-national corporations in the United States and the People's Republic of China. The company currently has offices in Texas, Florida, California, and Shanghai and Beijing, China. << << << About Standoutstocks.com Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button. Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market. Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |